ADHD and CBD in New Zealand: What the 2026 Research and Rule Changes Mean

Frequently Asked Questions

If you live with ADHD and have been wondering about medicinal cannabis or CBD oil in New Zealand, this guide explains the legal framework and what the 2026 rule changes mean for patients. Medicinal cannabis is a legal prescription medicine in NZ. Whether it might be appropriate for your specific situation is a conversation for a registered doctor.

Quick summary: Medicinal cannabis is a legal prescription medicine in New Zealand. People with ADHD sometimes ask whether it is something to consider alongside their existing care. A consultation with a registered doctor discusses whether medicinal cannabis may be appropriate. ADHD diagnosis and ongoing management remain with the patient’s GP, specialist, or psychiatrist.

Medically Reviewed by: Dr Waseem Alzaher

Is medicinal cannabis legal in New Zealand?

Yes. Medicinal cannabis is a legal, prescription-only medicine in Aotearoa, regulated under the Medicinal Cannabis Scheme.¹ A registered doctor or nurse practitioner decides whether to prescribe it based on each patient’s specific circumstances.

Since the formal Medicinal Cannabis Scheme started in 2020, the framework has moved cannabis out of the lifestyle category and into professional medical care.² For anyone considering this pathway, two things matter. First, you know what is in the bottle because every product has to meet the government’s Minimum Quality Standard (MQS). Second, you have legal protection at work and on the road, provided you follow your doctor’s instructions.

By 2026, the system will be well established. Local growing and manufacturing have expanded, which is a meaningful shift away from the old Green Fairy era, where potency and purity were unpredictable.

What the 2026 ADHD prescribing changes mean

If you have been following the news, you will know that 2026 brought changes to how ADHD is diagnosed and treated in New Zealand. From 1 February 2026, vocationally registered specialist GPs and nurse practitioners can diagnose and initiate adult ADHD treatment without a psychiatrist signing off first.³

Psychiatrist waitlists had become a real barrier to care for years. The new rules were designed to get people the help they need faster.³

This change applies to ADHD care more broadly. It does not affect the medicinal cannabis pathway directly. Your ADHD diagnosis and care plan continue to sit with your GP, specialist GP, nurse practitioner, or psychiatrist. A medicinal cannabis consultation is a separate conversation with a registered doctor about whether medicinal cannabis may be appropriate alongside your existing care.

Want to talk through what a medicinal cannabis consultation involves? Book a consultation.

How does CBD work in the body?

CBD interacts with the endocannabinoid system, or ECS. A simple way to think of the ECS is as a volume control sitting across the body’s signalling pathways, helping regulate how neurotransmitters communicate between cells.⁴

Most brain signals travel forward from one cell to the next. Endocannabinoids are different. They are produced on demand and travel backward, which allows the receiving cell to tell the sender to quieten down or speed up.⁴

Researchers have been interested in how the ECS interacts with dopamine pathways since dopamine signalling appears to behave a little differently in people with ADHD.⁴ Whether plant cannabinoids like CBD interact with these pathways in clinically meaningful ways is an area of active research rather than a settled clinical conclusion.

What does research say about CBD and core ADHD symptoms?

The evidence here is still developing. Some small trials have explored hyperactivity and focus, but the large, long-term studies that would be needed to draw firm conclusions about CBD and core ADHD symptoms are not yet available.⁵

Researchers are interested in how CBD interacts with the brain’s signalling systems, including the pathways that handle focus and self-regulation. Because everyone’s brain chemistry is different, what an individual experiences may vary. Whether medicinal cannabis is appropriate for any specific person is a conversation for a prescriber.

What has research explored about CBD, anxiety, and sleep?

Around half of adults with ADHD also live with an anxiety disorder.⁶ A New Zealand study published in 2020 followed 400 patients prescribed CBD and recorded what they reported about their quality of life, including their experience of anxiety and mental distress.⁷ The findings are published in BJGP Open if you would like to read them.

Sleep is another area researchers have looked at. ADHD medications can sometimes make it harder to wind down at the end of the day. International research has examined how patients prescribed CBD report on sleep, and how CBD interacts with the body’s sleep regulation systems.⁸ This is an area of active research rather than a settled clinical conclusion.

Using CBD alongside ADHD stimulants: what to be aware of

If you are already on ADHD stimulants, adding any new medication, including medicinal cannabis, is a conversation to have with your prescriber. A consultation can cover topics such as:

• Heart health. Stimulants and THC can both affect heart rate and blood pressure. The effects can interact, which is one reason your prescribing doctor will review your full medication list and any cardiovascular history.
• Dopamine pathways. Stimulants and THC both touch dopamine pathways in different ways. Research suggests long-term, high THC use can affect dopamine signalling.⁹ Product type and timing are decisions your prescriber will discuss with you based on your specific circumstances.
• Dose timing. Any timing of doses, product type, or formulation is a decision for your prescriber, based on your specific circumstances.

It is also worth flagging that higher THC is not automatically better. What matters is the cannabinoid profile and how it fits a specific person’s situation, not raw potency.

Why the NZ Minimum Quality Standard matters

If you care about what you are putting in your body, the legal framework is your protection. Every legal medicinal cannabis product must pass the Minimum Quality Standard (MQS).¹⁰ This means every batch is tested for purity (heavy metals, pesticides, mould), consistency (so the cannabinoid profile matches the label), and shelf life.

You do not get any of this from Green Fairies or an unregulated supply. For anyone considering a prescription medicine, a verified product is a basic safety requirement, and the MQS is what gives prescribers and patients confidence in what is actually in the bottle.

Key takeaways

• Medicinal cannabis is a legal, prescription-only medicine in New Zealand.
• The 1 February 2026 rule change allows specialist GPs and nurse practitioners to diagnose and initiate adult ADHD treatment without a psychiatrist’s sign-off.
• ADHD diagnosis and management sit with your GP, specialist, or psychiatrist. A medicinal cannabis consultation is a separate conversation about whether medicinal cannabis may be appropriate alongside that.
• Research is ongoing into how CBD and other cannabinoids interact with the brain. Areas of active research include focus, anxiety, and sleep.
• The Minimum Quality Standard means every legal product is tested for purity and consistency.
• Higher THC is not automatically better.

How to book a medicinal cannabis consultation in NZ

The 2026 legal landscape gives Kiwis clearer access to a regulated medicinal cannabis pathway than ever before. If you have been wondering whether it might be worth exploring as part of an honest conversation with your healthcare team, the next step is straightforward. You can take the 60 Second Eligibility Quiz or Book A Consultation if you would prefer to ask questions first.

References

1. Ministry of Health NZ. Medicinal cannabis: information for consumers. https://www.health.govt.nz/regulation-legislation/medicinal-cannabis/information-for-consumers
2. New Zealand Government. Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018. https://www.legislation.govt.nz/act/public/2018/0058/latest/DLM7518107.html
3. Ministry of Health NZ. Changes to ADHD prescribing rules from 1 February 2026. https://www.health.govt.nz/news/changes-to-adhd-prescribing-rules-from-1-february-2026
4. Lu, H. C., & Mackie, K. (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry, 79(7), 516-525. https://doi.org/10.1016/j.biopsych.2015.07.028
5. Cooper, R. E., Williams, E., Seegobin, S., Tye, C., Kuntsi, J., & Asherson, P. (2017). Cannabinoids in attention deficit/hyperactivity disorder: A randomised controlled trial. European Neuropsychopharmacology, 27(8), 795-808. https://doi.org/10.1016/j.euroneuro.2017.05.005
6. Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017). Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry, 17(1), 302. https://doi.org/10.1186/s12888-017-1463-3
7. Gulbransen, G., Xu, W., & Arroll, B. (2020). Cannabidiol prescription in clinical practice: an audit of 400 patients in New Zealand. BJGP Open, 4(1). https://doi.org/10.3399/bjgpopen20X101010
8. Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in anxiety and sleep: a large case series. The Permanente Journal, 23(1), 18-041. https://doi.org/10.7812/tpp/18-041
9. Bloomfield, M. A., Ashok, A. H., Volkow, N. D., & Howes, O. D. (2016). The effects of THC on the dopamine system. Nature, 539(7629), 369-377. https://doi.org/10.1038/nature20153
10. Ministry of Health NZ. Medicinal cannabis Minimum Quality Standard. https://www.health.govt.nz/regulation-legislation/medicinal-cannabis/information-for-health-professionals/minimum-quality-standard-medicinal-cannabis-products